Favorable outcomes were observed among patients with vitiligo who received systemic Janus kinase inhibitors, with tofacitinib associated with the highest rate of complete resolution. Tofacitinib may ...

An expert discusses how insurance coverage barriers for Janus kinase (JAK) inhibitors in vitiligo treatment can be overcome ...

Please provide your email address to receive an email when new articles are posted on . Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from ...

SCENESSE® is being evaluated as a systemic repigmentation therapy for vitiligo patients, with a clinical focus on adolescent (12 years and above) and adult patients with darker skin types (Fitzpatrick ...

Patients reported quality-of-life benefits from treatment for nonsegmental vitiligo, even when clinical improvement started slowly. From a clinical standpoint, vitiligo is marked by the progressive ...